nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—TNF—psoriatic arthritis	0.932	1	CbGaD
Epinephrine—Skin necrosis—Methotrexate—psoriatic arthritis	0.00132	0.022	CcSEcCtD
Epinephrine—Rales—Methotrexate—psoriatic arthritis	0.00112	0.0187	CcSEcCtD
Epinephrine—Nephropathy—Methotrexate—psoriatic arthritis	0.000968	0.0161	CcSEcCtD
Epinephrine—Mydriasis—Prednisolone—psoriatic arthritis	0.000952	0.0159	CcSEcCtD
Epinephrine—Necrosis—Methylprednisolone—psoriatic arthritis	0.000888	0.0148	CcSEcCtD
Epinephrine—Tingling sensation—Methylprednisolone—psoriatic arthritis	0.000867	0.0144	CcSEcCtD
Epinephrine—Necrosis—Dexamethasone—psoriatic arthritis	0.000807	0.0134	CcSEcCtD
Epinephrine—Necrosis—Betamethasone—psoriatic arthritis	0.000807	0.0134	CcSEcCtD
Epinephrine—Tingling sensation—Betamethasone—psoriatic arthritis	0.000788	0.0131	CcSEcCtD
Epinephrine—Tingling sensation—Dexamethasone—psoriatic arthritis	0.000788	0.0131	CcSEcCtD
Epinephrine—Extravasation—Betamethasone—psoriatic arthritis	0.000726	0.0121	CcSEcCtD
Epinephrine—Extravasation—Dexamethasone—psoriatic arthritis	0.000726	0.0121	CcSEcCtD
Epinephrine—Contusion—Dexamethasone—psoriatic arthritis	0.000726	0.0121	CcSEcCtD
Epinephrine—Contusion—Betamethasone—psoriatic arthritis	0.000726	0.0121	CcSEcCtD
Epinephrine—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—CARD14—psoriatic arthritis	0.000719	0.0933	CbGpPWpGaD
Epinephrine—Necrosis—Prednisone—psoriatic arthritis	0.000703	0.0117	CcSEcCtD
Epinephrine—Memory impairment—Prednisone—psoriatic arthritis	0.000703	0.0117	CcSEcCtD
Epinephrine—Pulmonary oedema—Prednisolone—psoriatic arthritis	0.000676	0.0113	CcSEcCtD
Epinephrine—Skin exfoliation—Triamcinolone—psoriatic arthritis	0.000667	0.0111	CcSEcCtD
Epinephrine—Skin exfoliation—Methylprednisolone—psoriatic arthritis	0.000665	0.0111	CcSEcCtD
Epinephrine—Contusion—Prednisone—psoriatic arthritis	0.000632	0.0105	CcSEcCtD
Epinephrine—Pulmonary oedema—Triamcinolone—psoriatic arthritis	0.000621	0.0104	CcSEcCtD
Epinephrine—Pulmonary oedema—Methylprednisolone—psoriatic arthritis	0.00062	0.0103	CcSEcCtD
Epinephrine—Skin exfoliation—Betamethasone—psoriatic arthritis	0.000605	0.0101	CcSEcCtD
Epinephrine—Skin exfoliation—Dexamethasone—psoriatic arthritis	0.000605	0.0101	CcSEcCtD
Epinephrine—Necrosis—Methotrexate—psoriatic arthritis	0.000587	0.00979	CcSEcCtD
Epinephrine—Pulmonary oedema—Betamethasone—psoriatic arthritis	0.000564	0.00939	CcSEcCtD
Epinephrine—Pulmonary oedema—Dexamethasone—psoriatic arthritis	0.000564	0.00939	CcSEcCtD
Epinephrine—TNF—IL23-mediated signaling events—IL23R—psoriatic arthritis	0.00055	0.0714	CbGpPWpGaD
Epinephrine—Vomiting—Auranofin—psoriatic arthritis	0.00054	0.009	CcSEcCtD
Epinephrine—Extravasation—Methotrexate—psoriatic arthritis	0.000528	0.0088	CcSEcCtD
Epinephrine—Skin exfoliation—Prednisone—psoriatic arthritis	0.000527	0.00878	CcSEcCtD
Epinephrine—Nausea—Auranofin—psoriatic arthritis	0.000505	0.00841	CcSEcCtD
Epinephrine—Psychotic disorder—Methylprednisolone—psoriatic arthritis	0.000494	0.00823	CcSEcCtD
Epinephrine—Pulmonary oedema—Prednisone—psoriatic arthritis	0.000491	0.00818	CcSEcCtD
Epinephrine—TNF—IL23-mediated signaling events—IL23A—psoriatic arthritis	0.000468	0.0607	CbGpPWpGaD
Epinephrine—Sweating increased—Prednisolone—psoriatic arthritis	0.000464	0.00773	CcSEcCtD
Epinephrine—Psychotic disorder—Betamethasone—psoriatic arthritis	0.000449	0.00748	CcSEcCtD
Epinephrine—Psychotic disorder—Dexamethasone—psoriatic arthritis	0.000449	0.00748	CcSEcCtD
Epinephrine—Skin exfoliation—Methotrexate—psoriatic arthritis	0.00044	0.00733	CcSEcCtD
Epinephrine—TNF—Cytokines and Inflammatory Response—IL15—psoriatic arthritis	0.000435	0.0565	CbGpPWpGaD
Epinephrine—Sweating increased—Triamcinolone—psoriatic arthritis	0.000427	0.00711	CcSEcCtD
Epinephrine—Sweating increased—Methylprednisolone—psoriatic arthritis	0.000426	0.00709	CcSEcCtD
Epinephrine—Acute coronary syndrome—Prednisolone—psoriatic arthritis	0.000419	0.00698	CcSEcCtD
Epinephrine—Hypokalaemia—Dexamethasone—psoriatic arthritis	0.000418	0.00697	CcSEcCtD
Epinephrine—Hypokalaemia—Betamethasone—psoriatic arthritis	0.000418	0.00697	CcSEcCtD
Epinephrine—Myocardial infarction—Prednisolone—psoriatic arthritis	0.000416	0.00694	CcSEcCtD
Epinephrine—Pulmonary oedema—Methotrexate—psoriatic arthritis	0.00041	0.00684	CcSEcCtD
Epinephrine—Psychotic disorder—Prednisone—psoriatic arthritis	0.000391	0.00652	CcSEcCtD
Epinephrine—Sweating increased—Dexamethasone—psoriatic arthritis	0.000387	0.00645	CcSEcCtD
Epinephrine—Sweating increased—Betamethasone—psoriatic arthritis	0.000387	0.00645	CcSEcCtD
Epinephrine—Acute coronary syndrome—Triamcinolone—psoriatic arthritis	0.000385	0.00641	CcSEcCtD
Epinephrine—Acute coronary syndrome—Methylprednisolone—psoriatic arthritis	0.000384	0.0064	CcSEcCtD
Epinephrine—Haemoglobin—Prednisolone—psoriatic arthritis	0.000383	0.00638	CcSEcCtD
Epinephrine—Myocardial infarction—Triamcinolone—psoriatic arthritis	0.000383	0.00638	CcSEcCtD
Epinephrine—Myocardial infarction—Methylprednisolone—psoriatic arthritis	0.000382	0.00636	CcSEcCtD
Epinephrine—Haemorrhage—Prednisolone—psoriatic arthritis	0.000381	0.00635	CcSEcCtD
Epinephrine—Sweating—Methylprednisolone—psoriatic arthritis	0.000374	0.00622	CcSEcCtD
Epinephrine—Hypokalaemia—Prednisone—psoriatic arthritis	0.000364	0.00607	CcSEcCtD
Epinephrine—Hyperglycaemia—Dexamethasone—psoriatic arthritis	0.000359	0.00597	CcSEcCtD
Epinephrine—Hyperglycaemia—Betamethasone—psoriatic arthritis	0.000359	0.00597	CcSEcCtD
Epinephrine—Haemoglobin—Triamcinolone—psoriatic arthritis	0.000352	0.00587	CcSEcCtD
Epinephrine—Haemoglobin—Methylprednisolone—psoriatic arthritis	0.000352	0.00586	CcSEcCtD
Epinephrine—Haemorrhage—Triamcinolone—psoriatic arthritis	0.000351	0.00584	CcSEcCtD
Epinephrine—Haemorrhage—Methylprednisolone—psoriatic arthritis	0.00035	0.00583	CcSEcCtD
Epinephrine—Acute coronary syndrome—Dexamethasone—psoriatic arthritis	0.000349	0.00582	CcSEcCtD
Epinephrine—Acute coronary syndrome—Betamethasone—psoriatic arthritis	0.000349	0.00582	CcSEcCtD
Epinephrine—Hallucination—Methylprednisolone—psoriatic arthritis	0.000348	0.0058	CcSEcCtD
Epinephrine—Myocardial infarction—Betamethasone—psoriatic arthritis	0.000347	0.00579	CcSEcCtD
Epinephrine—Myocardial infarction—Dexamethasone—psoriatic arthritis	0.000347	0.00579	CcSEcCtD
Epinephrine—Cerebrovascular accident—Methotrexate—psoriatic arthritis	0.000342	0.00569	CcSEcCtD
Epinephrine—Arrhythmia—Prednisolone—psoriatic arthritis	0.000341	0.00567	CcSEcCtD
Epinephrine—Sweating increased—Prednisone—psoriatic arthritis	0.000337	0.00562	CcSEcCtD
Epinephrine—Erythema—Prednisolone—psoriatic arthritis	0.000332	0.00553	CcSEcCtD
Epinephrine—Haemoglobin—Betamethasone—psoriatic arthritis	0.00032	0.00533	CcSEcCtD
Epinephrine—Haemoglobin—Dexamethasone—psoriatic arthritis	0.00032	0.00533	CcSEcCtD
Epinephrine—Haemorrhage—Dexamethasone—psoriatic arthritis	0.000318	0.0053	CcSEcCtD
Epinephrine—Haemorrhage—Betamethasone—psoriatic arthritis	0.000318	0.0053	CcSEcCtD
Epinephrine—Hallucination—Betamethasone—psoriatic arthritis	0.000317	0.00527	CcSEcCtD
Epinephrine—Hallucination—Dexamethasone—psoriatic arthritis	0.000317	0.00527	CcSEcCtD
Epinephrine—Arrhythmia—Triamcinolone—psoriatic arthritis	0.000313	0.00522	CcSEcCtD
Epinephrine—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.000313	0.00521	CcSEcCtD
Epinephrine—Hyperglycaemia—Prednisone—psoriatic arthritis	0.000312	0.0052	CcSEcCtD
Epinephrine—Mental disorder—Methylprednisolone—psoriatic arthritis	0.000306	0.00511	CcSEcCtD
Epinephrine—TNF—Cytokines and Inflammatory Response—IL13—psoriatic arthritis	0.000306	0.0397	CbGpPWpGaD
Epinephrine—Erythema—Triamcinolone—psoriatic arthritis	0.000305	0.00508	CcSEcCtD
Epinephrine—Erythema—Methylprednisolone—psoriatic arthritis	0.000305	0.00507	CcSEcCtD
Epinephrine—Acute coronary syndrome—Prednisone—psoriatic arthritis	0.000304	0.00507	CcSEcCtD
Epinephrine—Myocardial infarction—Prednisone—psoriatic arthritis	0.000303	0.00504	CcSEcCtD
Epinephrine—TNF—IL27-mediated signaling events—IL17A—psoriatic arthritis	0.000291	0.0377	CbGpPWpGaD
Epinephrine—Hypertension—Prednisolone—psoriatic arthritis	0.000287	0.00477	CcSEcCtD
Epinephrine—Arrhythmia—Betamethasone—psoriatic arthritis	0.000284	0.00473	CcSEcCtD
Epinephrine—Arrhythmia—Dexamethasone—psoriatic arthritis	0.000284	0.00473	CcSEcCtD
Epinephrine—Haemoglobin—Prednisone—psoriatic arthritis	0.000278	0.00464	CcSEcCtD
Epinephrine—Haemorrhage—Prednisone—psoriatic arthritis	0.000277	0.00462	CcSEcCtD
Epinephrine—Erythema—Betamethasone—psoriatic arthritis	0.000277	0.00461	CcSEcCtD
Epinephrine—Erythema—Dexamethasone—psoriatic arthritis	0.000277	0.00461	CcSEcCtD
Epinephrine—Hallucination—Prednisone—psoriatic arthritis	0.000276	0.00459	CcSEcCtD
Epinephrine—TNF—IL27-mediated signaling events—IL12B—psoriatic arthritis	0.00027	0.035	CbGpPWpGaD
Epinephrine—Tachycardia—Prednisolone—psoriatic arthritis	0.000264	0.0044	CcSEcCtD
Epinephrine—Hypertension—Triamcinolone—psoriatic arthritis	0.000263	0.00439	CcSEcCtD
Epinephrine—Hypertension—Methylprednisolone—psoriatic arthritis	0.000263	0.00438	CcSEcCtD
Epinephrine—TNF—Cytokines and Inflammatory Response—IL12B—psoriatic arthritis	0.000262	0.034	CbGpPWpGaD
Epinephrine—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.000262	0.00436	CcSEcCtD
Epinephrine—Drowsiness—Methotrexate—psoriatic arthritis	0.000258	0.0043	CcSEcCtD
Epinephrine—TNF—Canonical NF-kappaB pathway—NOD2—psoriatic arthritis	0.000258	0.0334	CbGpPWpGaD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000257	0.00429	CcSEcCtD
Epinephrine—Flushing—Prednisone—psoriatic arthritis	0.000257	0.00428	CcSEcCtD
Epinephrine—Renal failure—Methotrexate—psoriatic arthritis	0.000254	0.00422	CcSEcCtD
Epinephrine—Arrhythmia—Prednisone—psoriatic arthritis	0.000247	0.00412	CcSEcCtD
Epinephrine—Sweating—Methotrexate—psoriatic arthritis	0.000247	0.00412	CcSEcCtD
Epinephrine—Insomnia—Prednisolone—psoriatic arthritis	0.000245	0.00408	CcSEcCtD
Epinephrine—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000244	0.00406	CcSEcCtD
Epinephrine—Paraesthesia—Prednisolone—psoriatic arthritis	0.000243	0.00405	CcSEcCtD
Epinephrine—Tachycardia—Triamcinolone—psoriatic arthritis	0.000243	0.00405	CcSEcCtD
Epinephrine—Mental disorder—Prednisone—psoriatic arthritis	0.000243	0.00404	CcSEcCtD
Epinephrine—Tachycardia—Methylprednisolone—psoriatic arthritis	0.000243	0.00404	CcSEcCtD
Epinephrine—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000241	0.00402	CcSEcCtD
Epinephrine—Erythema—Prednisone—psoriatic arthritis	0.000241	0.00402	CcSEcCtD
Epinephrine—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.000241	0.00401	CcSEcCtD
Epinephrine—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.00024	0.004	CcSEcCtD
Epinephrine—Hypertension—Dexamethasone—psoriatic arthritis	0.000239	0.00398	CcSEcCtD
Epinephrine—Hypertension—Betamethasone—psoriatic arthritis	0.000239	0.00398	CcSEcCtD
Epinephrine—Haemoglobin—Methotrexate—psoriatic arthritis	0.000233	0.00388	CcSEcCtD
Epinephrine—Haemorrhage—Methotrexate—psoriatic arthritis	0.000232	0.00386	CcSEcCtD
Epinephrine—Insomnia—Triamcinolone—psoriatic arthritis	0.000225	0.00375	CcSEcCtD
Epinephrine—Insomnia—Methylprednisolone—psoriatic arthritis	0.000225	0.00375	CcSEcCtD
Epinephrine—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000224	0.00373	CcSEcCtD
Epinephrine—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000223	0.00372	CcSEcCtD
Epinephrine—TNF—Apoptosis—LTA—psoriatic arthritis	0.000222	0.0288	CbGpPWpGaD
Epinephrine—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000222	0.00369	CcSEcCtD
Epinephrine—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000222	0.00369	CcSEcCtD
Epinephrine—Agitation—Prednisone—psoriatic arthritis	0.000222	0.00369	CcSEcCtD
Epinephrine—Tachycardia—Betamethasone—psoriatic arthritis	0.000221	0.00368	CcSEcCtD
Epinephrine—Tachycardia—Dexamethasone—psoriatic arthritis	0.000221	0.00368	CcSEcCtD
Epinephrine—TNF—IL23-mediated signaling events—IL17A—psoriatic arthritis	0.000219	0.0284	CbGpPWpGaD
Epinephrine—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.000218	0.00364	CcSEcCtD
Epinephrine—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.000218	0.00364	CcSEcCtD
Epinephrine—TNF—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000213	0.0277	CbGpPWpGaD
Epinephrine—PAH—SIDS Susceptibility Pathways—IL13—psoriatic arthritis	0.000209	0.0271	CbGpPWpGaD
Epinephrine—Hypertension—Prednisone—psoriatic arthritis	0.000208	0.00347	CcSEcCtD
Epinephrine—TNF—TNF receptor signaling pathway —TNFRSF1B—psoriatic arthritis	0.000207	0.0268	CbGpPWpGaD
Epinephrine—Insomnia—Dexamethasone—psoriatic arthritis	0.000204	0.00341	CcSEcCtD
Epinephrine—Insomnia—Betamethasone—psoriatic arthritis	0.000204	0.00341	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000204	0.0034	CcSEcCtD
Epinephrine—TNF—IL23-mediated signaling events—IL12B—psoriatic arthritis	0.000204	0.0264	CbGpPWpGaD
Epinephrine—Paraesthesia—Betamethasone—psoriatic arthritis	0.000203	0.00338	CcSEcCtD
Epinephrine—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000203	0.00338	CcSEcCtD
Epinephrine—Mental disorder—Methotrexate—psoriatic arthritis	0.000203	0.00338	CcSEcCtD
Epinephrine—Erythema—Methotrexate—psoriatic arthritis	0.000202	0.00336	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000195	0.00325	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000195	0.00325	CcSEcCtD
Epinephrine—Nervous system disorder—Prednisone—psoriatic arthritis	0.000193	0.00322	CcSEcCtD
Epinephrine—Tachycardia—Prednisone—psoriatic arthritis	0.000192	0.0032	CcSEcCtD
Epinephrine—Skin disorder—Prednisone—psoriatic arthritis	0.000191	0.00319	CcSEcCtD
Epinephrine—Hyperhidrosis—Prednisone—psoriatic arthritis	0.00019	0.00317	CcSEcCtD
Epinephrine—Dizziness—Prednisolone—psoriatic arthritis	0.000179	0.00298	CcSEcCtD
Epinephrine—Insomnia—Prednisone—psoriatic arthritis	0.000178	0.00297	CcSEcCtD
Epinephrine—Paraesthesia—Prednisone—psoriatic arthritis	0.000177	0.00294	CcSEcCtD
Epinephrine—Chest pain—Methotrexate—psoriatic arthritis	0.000172	0.00286	CcSEcCtD
Epinephrine—TNF—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000171	0.0222	CbGpPWpGaD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.00017	0.00284	CcSEcCtD
Epinephrine—Dizziness—Triamcinolone—psoriatic arthritis	0.000165	0.00274	CcSEcCtD
Epinephrine—Dizziness—Methylprednisolone—psoriatic arthritis	0.000164	0.00274	CcSEcCtD
Epinephrine—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000161	0.00269	CcSEcCtD
Epinephrine—Nausea—Prednisolone—psoriatic arthritis	0.000161	0.00268	CcSEcCtD
Epinephrine—Skin disorder—Methotrexate—psoriatic arthritis	0.00016	0.00266	CcSEcCtD
Epinephrine—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.000159	0.00265	CcSEcCtD
Epinephrine—Vomiting—Triamcinolone—psoriatic arthritis	0.000158	0.00264	CcSEcCtD
Epinephrine—Vomiting—Methylprednisolone—psoriatic arthritis	0.000158	0.00263	CcSEcCtD
Epinephrine—TNF—Cytokines and Inflammatory Response—HLA-DRB1—psoriatic arthritis	0.000154	0.02	CbGpPWpGaD
Epinephrine—Dizziness—Betamethasone—psoriatic arthritis	0.000149	0.00249	CcSEcCtD
Epinephrine—Dizziness—Dexamethasone—psoriatic arthritis	0.000149	0.00249	CcSEcCtD
Epinephrine—Insomnia—Methotrexate—psoriatic arthritis	0.000149	0.00248	CcSEcCtD
Epinephrine—Nausea—Triamcinolone—psoriatic arthritis	0.000148	0.00247	CcSEcCtD
Epinephrine—Paraesthesia—Methotrexate—psoriatic arthritis	0.000148	0.00246	CcSEcCtD
Epinephrine—Nausea—Methylprednisolone—psoriatic arthritis	0.000148	0.00246	CcSEcCtD
Epinephrine—Somnolence—Methotrexate—psoriatic arthritis	0.000146	0.00244	CcSEcCtD
Epinephrine—Vomiting—Dexamethasone—psoriatic arthritis	0.000144	0.00239	CcSEcCtD
Epinephrine—Vomiting—Betamethasone—psoriatic arthritis	0.000144	0.00239	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000142	0.00237	CcSEcCtD
Epinephrine—Nausea—Dexamethasone—psoriatic arthritis	0.000134	0.00224	CcSEcCtD
Epinephrine—Nausea—Betamethasone—psoriatic arthritis	0.000134	0.00224	CcSEcCtD
Epinephrine—TNF—Allograft Rejection—HLA-C—psoriatic arthritis	0.000131	0.0169	CbGpPWpGaD
Epinephrine—Dizziness—Prednisone—psoriatic arthritis	0.00013	0.00217	CcSEcCtD
Epinephrine—TNF—Allograft Rejection—IL13—psoriatic arthritis	0.00013	0.0168	CbGpPWpGaD
Epinephrine—TNF—Apoptosis—TNFRSF1B—psoriatic arthritis	0.000128	0.0166	CbGpPWpGaD
Epinephrine—TNF—TNF alpha Signaling Pathway—REL—psoriatic arthritis	0.000126	0.0163	CbGpPWpGaD
Epinephrine—Vomiting—Prednisone—psoriatic arthritis	0.000125	0.00209	CcSEcCtD
Epinephrine—ADRBK1—DAP12 interactions—HLA-C—psoriatic arthritis	0.000121	0.0157	CbGpPWpGaD
Epinephrine—TNF—Allograft Rejection—IL17A—psoriatic arthritis	0.000119	0.0155	CbGpPWpGaD
Epinephrine—TNF—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.000119	0.0154	CbGpPWpGaD
Epinephrine—Nausea—Prednisone—psoriatic arthritis	0.000117	0.00195	CcSEcCtD
Epinephrine—TNF—IL23-mediated signaling events—NOS2—psoriatic arthritis	0.000114	0.0148	CbGpPWpGaD
Epinephrine—TNF—Allograft Rejection—IL12B—psoriatic arthritis	0.000111	0.0144	CbGpPWpGaD
Epinephrine—ADRBK1—CXCR4-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.00011	0.0143	CbGpPWpGaD
Epinephrine—Dizziness—Methotrexate—psoriatic arthritis	0.000109	0.00181	CcSEcCtD
Epinephrine—Vomiting—Methotrexate—psoriatic arthritis	0.000105	0.00174	CcSEcCtD
Epinephrine—Nausea—Methotrexate—psoriatic arthritis	9.77e-05	0.00163	CcSEcCtD
Epinephrine—TNF—Vitamin B12 Metabolism—CRP—psoriatic arthritis	9.69e-05	0.0126	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—MEFV—psoriatic arthritis	9.2e-05	0.0119	CbGpPWpGaD
Epinephrine—TNF—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	9.05e-05	0.0117	CbGpPWpGaD
Epinephrine—TNF—Folate Metabolism—CRP—psoriatic arthritis	7.88e-05	0.0102	CbGpPWpGaD
Epinephrine—TNF—Allograft Rejection—HLA-B—psoriatic arthritis	7.72e-05	0.01	CbGpPWpGaD
Epinephrine—TNF—SIDS Susceptibility Pathways—IL13—psoriatic arthritis	7.53e-05	0.00977	CbGpPWpGaD
Epinephrine—ADRBK1—DAP12 interactions—HLA-B—psoriatic arthritis	7.17e-05	0.0093	CbGpPWpGaD
Epinephrine—TNF—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	7.07e-05	0.00917	CbGpPWpGaD
Epinephrine—TNF—Allograft Rejection—HLA-DRB1—psoriatic arthritis	6.54e-05	0.00848	CbGpPWpGaD
Epinephrine—TNF—Selenium Micronutrient Network—CRP—psoriatic arthritis	6.26e-05	0.00812	CbGpPWpGaD
Epinephrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	5.99e-05	0.00777	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—MEFV—psoriatic arthritis	5.36e-05	0.00695	CbGpPWpGaD
Epinephrine—PAH—SIDS Susceptibility Pathways—TNF—psoriatic arthritis	4.98e-05	0.00646	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—HLA-C—psoriatic arthritis	4.71e-05	0.00611	CbGpPWpGaD
Epinephrine—TNF—Spinal Cord Injury—NOS2—psoriatic arthritis	4.52e-05	0.00586	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—NOD2—psoriatic arthritis	3.46e-05	0.00449	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—REL—psoriatic arthritis	2.98e-05	0.00387	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—HLA-B—psoriatic arthritis	2.78e-05	0.00361	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—HLA-C—psoriatic arthritis	2.74e-05	0.00356	CbGpPWpGaD
Epinephrine—ADRBK1—Innate Immune System—CRP—psoriatic arthritis	2.46e-05	0.00319	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—NOD2—psoriatic arthritis	2.02e-05	0.00262	CbGpPWpGaD
Epinephrine—PAH—Disease—NOS2—psoriatic arthritis	1.89e-05	0.00246	CbGpPWpGaD
Epinephrine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	1.67e-05	0.00216	CbGpPWpGaD
Epinephrine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	1.67e-05	0.00216	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—HLA-B—psoriatic arthritis	1.62e-05	0.0021	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—CRP—psoriatic arthritis	1.43e-05	0.00186	CbGpPWpGaD
Epinephrine—ADRBK1—Immune System—HLA-DRB1—psoriatic arthritis	1.37e-05	0.00178	CbGpPWpGaD
Epinephrine—ADRBK1—Disease—NOS2—psoriatic arthritis	1.21e-05	0.00157	CbGpPWpGaD
Epinephrine—ADRA2B—Hemostasis—NOS2—psoriatic arthritis	1.18e-05	0.00153	CbGpPWpGaD
Epinephrine—ADRA2C—Hemostasis—NOS2—psoriatic arthritis	1.1e-05	0.00143	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—NOS2—psoriatic arthritis	8.93e-06	0.00116	CbGpPWpGaD
